Callio Therapeutics Secures $187M to Revolutionize Off-the-Shelf Blood Stem Cell Therapies

Garuda Therapeutics is proud to announce a monumental funding milestone with a fresh capital infusion of $187,000,000, marking a pivotal step in our mission to revolutionize stem cell therapy.

Our platform technology, designed to generate off-the-shelf, self-renewing blood stem cells, represents a breakthrough in eliminating the longstanding dependency on donor or patient cells for blood stem cell transplants.

This innovation is set to provide patients with rapid, broad access to consistent, durable, and HLA-compatible transgene-free therapies—transforming the treatment landscape for more than 120 diseases.

Much like the life-saving promise of bone marrow transplants, our approach is positioned to offer potentially curative solutions that bring hope to countless patients worldwide.

This significant funding will empower us to accelerate our research and development initiatives, advancing our clinical trials and expanding our manufacturing capabilities to meet growing global demand.

With this investment, we aim to foster strategic partnerships and streamline regulatory pathways, ensuring that our revolutionary therapies reach those in need with unprecedented speed and reliability.

The robust support from our investors not only underscores their confidence in our scientific vision but also reaffirms our commitment to overcoming the limitations of current stem cell therapies.

At Garuda Therapeutics, every breakthrough brings us closer to a future where donor scarcity and compatibility challenges are relics of the past, and where every patient can access life-changing cures.

With renewed momentum and substantial resources, we are poised to transform the standard of care in regenerative medicine, driving forward our vision for a healthier, more equitable world.